Autopsy report · NCT04320771
Study on the Safety of Neladenoson Bialanate, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Dug Given as a Single Oral Dose of 10 mg Immediate Release Tablet in Participants With Renal Impairment and Healthy Participants Matched for Age-, Gender-, and Weight
Cause of deathFunding or business
“Termination of the development project for Neladenoson bialanate”
Life of this trial
- Registered 2 years 5 months after it had already started.
- Ran for about 1 year 1 month before it stopped.
- 18 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1
- Sponsor
- Bayer
- Sponsor type
- Industry
- Conditions
- Pharmacology, Clinical
- Interventions
- Neladenoson bialanate (BAY 1067197)
- Participants
- 18
- Sites
- 2
- Countries
- Germany
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.